Praecis to present update on its DirectSelect technology at MedChem Europe

By Lisa Kerner

Erie, Pa., Feb. 22 - Praecis Pharmaceuticals, Inc. is presenting an update on the development of its DirectSelect technology at the MedChem Europe 2006 meeting in Prague, Czech Republic.

DirectSelect is a chemical-driven technology that Praecis believes will facilitate the drug discovery process.

The technology is based on the creation of multiple, numerically large, encoded libraries of drug-like structures. These libraries can be rapidly screened to identify individual structures, or families of structures, with affinity for a macromolecular target, according to a company news release.

The company's presentation, delivered by Dr. Barry Morgan, vice president, chemistry, will include a discussion regarding the generation of a set of libraries comprising more than 5 billion compounds geared toward the identification of small molecule drug candidates.

The odds of identifying hits with higher affinity and enhanced selectivity for a macromolecular target can be improved by increasing the numeric size and "chemical space" interrogated by the target, the company said. Also, access to multiple, structurally diverse families should improve the likelihood of identifying a lead molecule with a favorable safety profile in vivo.

Praecis said it intends to use its DirectSelect technology to support pharmaceutical partnerships in drug discovery and development, as well as expand its own proprietary development pipeline.

Praecis is a biopharmaceutical company focused on the discovery and development of innovative therapies that either address unmet medical needs or offer improvements over existing therapies. The company is located in Waltham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.